Search
for

    Learn

    2 / 2 results

      learn GT20029

      research compound made to degrade androgen receptors in scalp

      learn KY19382

      compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles

    Research

    5 / 14 results

    Community Join

    5 / 223 results

      community GT20029 & KX826 Major Updates from Kintor.

      in Research/Science  98 upvotes 3 weeks ago
      KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

      community gt20029 any u-lab order possible?

      in Product  7 upvotes 6 months ago
      The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

      community GT20029 - Promising phase II results

      in Research/Science  15 upvotes 7 months ago
      GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

      community Breaking hair loss news! GT20029 is a resounding success!

      in Product  132 upvotes 8 months ago
      GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.